Clinical Study of Ibrutinib in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
10.19746/j.cnki.issn.1009-2137.2025.03.023
- Author:
Yu-Ning YAO
1
;
Hao JIANG
2
;
Lu-Min TANG
1
;
Ye LOU
3
Author Information
1. Department of Hematology,Daqing People's Hospital, Daqing 163316, Heilongjiang Province, China.
2. Neurology Department, Daqing People's Hospital, Daqing 163316, Heilongjiang Province, China.
3. Department of Hematology, Longnan Hospital of Daqing City, Daqing 163458, Heilongjiang Province, China.
- Publication Type:Journal Article
- Keywords:
relapsed/refractory diffuse large B-cell lymphoma;
ibrutinib;
clinical effects;
safety
- MeSH:
Humans;
Piperidines/therapeutic use*;
Lymphoma, Large B-Cell, Diffuse/drug therapy*;
Adenine/therapeutic use*;
Rituximab/therapeutic use*;
Lenalidomide/therapeutic use*;
Male;
Female;
Middle Aged;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*;
Adult;
Aged;
Pyrimidines/therapeutic use*;
Pyrazoles/therapeutic use*;
Treatment Outcome
- From:
Journal of Experimental Hematology
2025;33(3):784-788
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To study the clinical effects of ibrutinib in the treatment of relapsed/refractory diffuse large B-cell lymphoma (RRDLBCL).
METHODS:A total of 101 patients with RRDLBCL in Daqing People's Hospital from September 2019 to September 2022 were selected. 45 patients were received ibrutinib monotherapy, 36 patients were received a combination therapy of ibrutinib, rituximab, and lenalidomide, and 20 patients were received a combination therapy of ibrutinib and lenalidomide. The clinical effects were observed.
RESULTS:The median duration of treatment for all patients was 4 (2-9) months. The disease control rates(DCR) and objective response rates(ORR) in the ibrutinib monotherapy group were 46.67% and 26.67%, respectively. In the combination therapy group of ibrutinib, rituximab, and lenalidomide, the DCR and ORR were 69.44% and 44.44%, respectively. In the combination therapy group of ibrutinib and lenalidomide, the DCR and ORR were 60.00% and 35.00%, respectively. The DCR and ORR in the combination therapy group of ibrutinib, rituximab, and lenalidomide were significantly higher than those in the ibrutinib monotherapy group (P < 0.05). There were no significant differences in DCR and ORR between the combination therapy group of ibrutinib and lenalidomide and the ibrutinib monotherapy group (P >0.05). The median follow-up time of all patients was 15 (5-35) months, with a median overall survival(OS) of 21.0 (15.8-26.2) months and a median progression-free survival(PFS) of 14.0 (12.1-15.9) months. In the ibrutinib monotherapy group, the median OS and PFS were 15.0 (12.1-17.9) months and 12.0 (11.0-13.0) months, respectively. In the combination therapy group of ibrutinib and lenalidomide, the median OS and PFS were 22.0 (13.3-30.7) months and 16.0 (14.1-19.7) months, respectively. In the combination therapy group of ibrutinib, rituximab, and lenalidomide, the median OS and PFS were 23.0 (19.7-26.3) months and 17.0 (14.8-19.1) months, respectively. The median OS and PFS in the combination therapy group of ibrutinib, rituximab, and lenalidomide were significantly higher than those in the ibrutinib monotherapy group (P < 0.05). There were no significant differences in median OS and PFS between the combination therapy group of ibrutinib and lenalidomide and the combination therapy group of ibrutinib, rituximab, and lenalidomide (P >0.05). Hematological adverse reactions included neutropenia in 14 cases (13.86%), thrombocytopenia in 16 cases (15.84%), and leukopenia in 13 cases (12.87%). Non-hematological adverse reactions mainly included nausea and vomiting in 33 cases (32.67%) and fatigue in 44 cases (43.56%).
CONCLUSION:Ibrutinib has certain clinical effects and good safety in the treatment of RRDLBCL.
